Organon & Co. (OGN)
13.76
+0.02
(+0.15%)
USD |
NYSE |
Oct 15, 16:00
13.76
0.00 (0.00%)
Pre-Market: 20:00
Organon Research and Development Expense (Quarterly) : 90.00M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 90.00M |
| March 31, 2026 | 93.00M |
| December 31, 2025 | 91.00M |
| September 30, 2025 | 84.00M |
| June 30, 2025 | 95.00M |
| March 31, 2025 | 96.00M |
| December 31, 2024 | 130.00M |
| September 30, 2024 | 111.00M |
| June 30, 2024 | 116.00M |
| March 31, 2024 | 112.00M |
| December 31, 2023 | 134.00M |
| September 30, 2023 | 137.00M |
| June 30, 2023 | 128.00M |
| Date | Value |
|---|---|
| March 31, 2023 | 129.00M |
| December 31, 2022 | 139.00M |
| September 30, 2022 | 127.00M |
| June 30, 2022 | 106.00M |
| March 31, 2022 | 96.00M |
| December 31, 2021 | 189.00M |
| September 30, 2021 | 111.00M |
| June 30, 2021 | 76.00M |
| March 31, 2021 | 67.00M |
| December 31, 2020 | 60.00M |
| September 30, 2020 | 54.00M |
| June 30, 2020 | 51.00M |
| March 31, 2020 | 45.00M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Merck & Co., Inc. | 9.229B |
| Viatris, Inc. | 245.20M |
| Pfizer Inc. | 2.746B |
| Pacira Biosciences, Inc. | 30.24M |
| Bristol Myers Squibb Co. | 2.316B |